Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (2026)
28 slides from Maia Biotechnology's investor presentation, 2026
Slide 1: Telomere Targeting Immunotherapies for Cancer
TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA Fall 2026 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; sta
Slide 3: MAIA Biotechnology - Investment Profile
MAIA BIOTECHNOLOGY - INVESTMENT PROFILE NYSE American: MAIA New science for cancer therapy with dual mechanism of action: Telomere Targeting and Immunogenicity • Ateganosine (THIO): lead molecule in 2 ongoing clinical trials (Phase 3 and Phase 2) • Second generation compounds in R&D ❑ Phase 3 Trial
Slide 4: Achievements to Date
ACHIEVEMENTS TO DATE NYSE American: MAIA Ateganosine (THIO) is the only direct telomere-targeting anticancer agent in clinical development Regulatory achievements to date Multiple Ateganosine (THIO) + • 3 U.S. FDA Orphan Drug Designations: checkpoint inhibitor trials planned • Hepatocellular Carcino
Slide 5: Robust Pipeline
ROBUST PIPELINE NYSE American: MAIA Clinical Trials with Ateganosine Worldwide rights Clinical Trial Indication Treatment Status owned by MAIA THIO-104 NSCLC-3 Ateganosine → Libtayo® Ongoing Phase 3 Clinical supply agreement THIO-101 NSCLC-3 Ateganosine → Libtayo® Ongoing Phase 2 THIO-CRC CRC-3 Ateg
Slide 6: Mechanism of Action
MECHANISM OF ACTION NYSE American: MAIA Ateganosine (THIO, 6-thio-2'-deoxyguanosine) has a novel dual mechanism of action A Telomere-Targeting In cancer cells • Ateganosine is a guanine analog incorporated into telomeres by telomerase, active in >80% of cancers. Chromosome • This disrupts telomere s
Slide 7: Curative Preclinical Studies
CURATIVE PRECLINICAL STUDIES NYSE American: MAIA In Non-Small Cell Lung Cancer (NSCLC) Cycle 1 Cycle 2 Control 1000 Atezolizumab models, Ateganosine followed by CPI 2 cycles of treatment Ateganosine results in 60% complete response (CR) 900 Ateganosine → Atezolizumab 800 Tumor Volume (mm3) Only 2 cy
Slide 8: Potential for Partnerships
POTENTIAL FOR PARTNERSHIPS NYSE American: MAIA Examples of commercially Ateganosine followed by a CPI available CPIs has the potential to change (pembrolizumab) (atezolizumab) the treatment landscape of multiple tumor types (nivolumab) Great potential for expansion (cemiplimab) (tislelizumab) • Stud
Slide 9: NSCLC Clinical Trials
NYSE American: MAIA NSCLC CLINICAL TRIALS NYSE American: MAIA 9 9
Slide 10: Phase 2 Trial Ongoing (THIO-101)
PHASE 2 TRIAL ONGOING NYSE American: MAIA THIO-101: A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Parts A & B (Completed)
Slide 11: Robust Efficacy to Support Phase 3 Trial
ROBUST EFFICACY TO SUPPORT PHASE 3 TRIAL NYSE American: MAIA Observed outcomes from THIO-101 (Parts A and B): THIO-101 - Overall Survival (3L) 1.00 THIO-101 Chemo (RWD) mOS 17.8 months (3L) ~5.8 months1 0.75 DCR 88% (3L 180mg) ~25-35%1-2 OS 0.50 ORR 38% (3L 180mg) ~6-10%1 0.25 95% CI lower bound: 12
Slide 12: Phase 3 Trial Designed for Highest Potential
PHASE 3 TRIAL DESIGNED FOR HIGHEST POTENTIAL NYSE American: MAIA THIO-104: A Multicenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors and Chemotherapy
Slide 13: High Probability of Technical Success
HIGH PROBABILITY OF TECHNICAL SUCCESS NYSE American: MAIA • OS is the primary endpoint • 90% power to detect HR=0.62, median 9.4 months vs 5.8 months1 (chemo) THIO-104 Design • Interim analysis boundary 1-sided p<0.0074 at 131 deaths • Final analysis boundary 1-sided p<0.0228 at 186 deaths Bayesian
Slide 14: Market Entry Strategy - Summary
MARKET ENTRY STRATEGY - SUMMARY NYSE American: MAIA 3L NSCLC is an excellent market entry segment: Highly unmet medical need The immunotherapy-resistant and chemotherapy-resistant population desperately need other options No standard of care Lack of established treatment and guidelines for patients
Slide 15: Planned Trials in Other Tumor Types
NYSE American: MAIA PLANNED TRIALS IN OTHER TUMOR TYPES NYSE American: MAIA 15 15
Slide 16: Complete Responses Observed in CRC
COMPLETE RESPONSES OBSERVED IN CRC NYSE American: MAIA 700 Control Preclinical Studies in Colorectal Cancer Tumor Volume (mm3) 600 Atezolizumab Ateganosine Ateganosine (THIO) followed by CPI 500 Ateganosine → Atezo results in 100% complete response 400 300 200 100% CR Only 2 cycles of therapy were 1
Slide 17: Vast Number of Studies in Liver Cancer
VAST NUMBER OF STUDIES IN LIVER CANCER NYSE American: MAIA Preclinical Studies in Hepatocellular Carcinoma Ateganosine (THIO) achieved complete and durable responses in Hepatocellular Carcinoma 1500 HCC (HCC), the dominant histology in primary liver Tumor Volume (mm3) Control 1250 cancer (90%) Atega
Slide 18: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY NYSE American: MAIA Sustained Anti-Tumor Response Control Ateganosine Libtayo • When combined with Ateganosine+Libtayo immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated • Upon rechallenge with two times HCC more cancer cells and n
Slide 19: Great Potential in SCLC
GREAT POTENTIAL IN SCLC NYSE American: MAIA Preclinical Studies in Small Cell Lung Cancer Ateganosine (THIO) is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung 1500 Control Carcinoma (SCLC) in vivo in humanized murine Tumor Volume (mm3) cancer model (H2081) 1250 Pembro → Ateganosin
Slide 20: Multiple Trials Planned in Other Cancers
MULTIPLE TRIALS PLANNED IN OTHER CANCERS NYSE American: MAIA Multicenter, Open-label, Phase 2 Trials Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Tislelizumab in CRC, SCLC and HCC Part A/B: Safety/Efficacy Signal (n=~40) Part C: Pivotal Phase 2 (n=~80) Atega
Slide 21: Investment Opportunity
NYSE American: MAIA INVESTMENT OPPORTUNITY NYSE American: MAIA 21 21
Slide 22: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM NYSE American: MAIA Vlad Vitoc, MD, Sergei Gryaznov, Jeffrey Himmelreich, MBA PhD MBA Founder and CEO Chief Scientific Officer Head of Finance • 25+ years in Oncology Pharma/ • 26+ years as Scientist • 20+ years of financial expertise Biotech: Commercial, Medical • Expert
Slide 23: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY NYSE American: MAIA Goal: New Chemical Entity (NCE) Marketing Exclusivity Robust and Growing Patent Portfolio for THIO Ateganosine (THIO) has never been previously approved by the FDA for 10 36 issued patents Europe Pending Patent commercialization Validated in
Slide 24: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY NYSE American: MAIA NSCLC is only the beginning. MAIA is developing therapies for the top tumor types markets globally. • NSCLC market is expanding to $70B. Ateganosine holds substantial commercial opportunity in a projected $70 billion global NSCLC treatment market by
Slide 25: Thank You
NYSE American: MAIA THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 NYSE American: MAIA 25 25
Slide 26: Appendix
NYSE American: MAIA APPENDIX NYSE American: MAIA 26 26
Slide 27: THIO-101 - Baseline Characteristics (Parts A & B)
THIO-101 - BASELINE CHARACTERISTICS (PARTS A & B) NYSE American: MAIA • At the time of cutoff June 30, 2025, 60 mg 180 mg 360 mg Total Characteristic (n=24) (n=41) (n=14) (N=79) 79 subjects with advanced NSCLC Median age (range), years 67 (52–85) 68 (45–81) 68 (50–75) 67 (45–85) received at least on
Slide 28: THIO-101 - Safety Summary (Parts A & B)
THIO-101 - SAFETY SUMMARY (PARTS A & B) NYSE American: MAIA • Overall, as of the cut-off date 15Jan2025, THIO + cemiplimab been generally well tolerated in a heavily pre- treated population, with most events being Grade 1–2 in severity. • Most Treatment Emergent Adverse Events (TEAEs) were laborator